Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2068-2073

  Rhodes, Nathaniel J ^a,b   Gardiner, Bradley J ^c   Neely, Michael N ^d,e   Grayson, M Lindsay ^c,f   Ellis, Andrew G ^c,f   Lawrentschuk, Nathan ^f,g   Frauman, Albert G ^c,f   Maxwell, Kelly M ^h   Zembower, Teresa R ^h   Scheetz, Marc H ^a,b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c AUSTIN HEALTH   (Australia)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug administration schedule; Pharmacokinetics; Prostate

Indexed keywords

FOSFOMYCIN;

AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; ESCHERICHIA COLI; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; POSTOPERATIVE INFECTION; PROPHYLAXIS; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION;

EID: 84936944556     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv067     Document Type: Article

References (21)

1. Grabe M, Bjerklund-Johansen TE, Botto H et al. Perioperative antibacterial prophylaxis in urology. In: Guidelines on Urological Infections. Arnhem: European Association of Urology (EAU), 2011; 78-93.
2. Wolf JS Jr, Bennett CJ, Dmochowski RR et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179: 1379-90.
3. Davidson AJ, Webb DR, Lawrentschuk N et al. Multi-resistant Escherichia coli sepsis following transrectal ultrasound-guided prostate biopsy. Br J Hosp Med (Lond) 2006; 67: 98-9.
4. Williamson DA, Barrett LK, Rogers BA et al. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 2013; 57: 267-74.
5. Cek M, Tandogdu Z, Naber K et al. Antibiotic prophylaxis in urology departments, 2005-2010. Eur Urol 2013; 63: 386-94.
6. Liss MA, Chang A, Santos R et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 2011; 185: 1283-8.
7. Gardiner BJ, Mahony AA, Ellis AG et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis 2014; 58: e101-5.
8. Ongun S, Aslan G, Avkan-Oguz V. The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int 2012; 89: 439-44.
9. Wagenlehner FM, Thomas PM, Naber KG. Fosfomycin trometamol (3, 000 mg) in perioperative antibiotic prophylaxis of healthcareassociated infections after endourological interventions: a narrative review. Urol Int 2014; 92: 125-30.
10. Leary R, Jelliffe R, Schumitzky A et al. An adaptive grid nonparametric approach to pharmacokinetic and dynamic (PK/PD) population models. In: Computer Based Medical Systems 2001. Proceedings of the Fourteenth IEEE Symposium on Computer-Based Medical Systems, Bethesda, MD, 2001. 389-94.
11. Neely MN, van Guilder MG, Yamada WM et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34: 467-76.
12. Tatarinova T, Neely M, Bartroff J et al. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn 2013; 40: 189-99.
13. Forest Pharmaceuticals. MONUROL (Fosfomycin Tromethamine) SACHET Package Insert. St Louis, MO: Forest Laboratories, Inc., 2007.
14. Goutelle S, Bourguignon L, Maire P et al. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009; 53: 2974-81.
15. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 3.1, 2013. http://www.eucast.org.
16. Lindstedt S, Lindstrom U, Ljunggren E et al. Single-dose antibiotic prophylaxis in core prostate biopsy: impact of timing and identification of risk factors. Eur Urol 2006; 50: 832-7.
17. Dan M, Golomb J, Gorea A et al. Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother 1986; 30: 88-9.
18. Drusano GL, Preston SL, Van Guilder M et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44: 2046-51.
19. Lugg J, Lettieri J, Stass H et al. Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single,
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.
21. Pulcini C, Bush K, Craig WA et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012; 54: 268-74.